Case Study 32 Esophageal Cancer Treated With Surgery And Radiation

Abstract

To assess if surgery provided survival benefit to patients with esophageal squamous cell carcinoma (SCC), we performed a retrospective review of 1230 patients who were newly diagnosed with stage T2-T4 esophageal SCC from 2007 to 2014 in our hospital. There were greater than 70% of patients with age under 65 years, and more than 85% were stage T3-T4 at the time of diagnosis. The median survival time was 1.06 year (95% CI 0.99–1.1 yrs). Survival analyses showed that survival time was significantly associated with age, T stage, clinical lymph node involvement and treatment modality (surgery versus definite chemoradiotherapy). Surgery still possessed a powerful impact on overall survival by multivariable analysis. Death risk of patients treated with curative surgery was significantly lower than those with definite chemoradiotherapy. Furthermore, for patients of stage T3N(+) and T4, surgery combined with (neo-)adjuvant treatment were significantly associated with higher survival rate than surgery alone or definite chemoradiotherapy. In conclusion, the patients who undergo surgery were significantly associated longer survival, therefore, curative resection should be considered for esophageal cancer patients who are medically fit for surgery. Moreover, combined with (neo-)adjuvant treatment is recommended for surgically resectable stage T3-T4 esophageal SCC.

Esophageal carcinoma is one of the most common cancers, and considered a serious malignancy with respect to prognosis and mortality rate1. Despite many advances in diagnosis and treatment, esophageal cancer still is an aggressive disease, characterized by a high degree of locoregional and distant recurrence and poor overall survival2,3. Surgery is a major component of treatment for resectable esophageal cancer, especially for adenocarcinoma. Surgery has been regarded as mainstay of cure for esophageal cancer in the past although distant control and complete resection rate remain issues with surgery4,5. The postoperative mortality6,7 and higher rate of relapse with esophagectomy have prompted investigation of multidisciplinary management, such as concomitant chemoradiotherapy (CCRT) with or without surgery8,9,10. However, the most appropriate treatment modality for esophageal cancer is still controversial. Within the past decade, several studies investigating the curative potential of CCRT have challenged the idea that surgery is an indispensable part of curative therapy11,12. Factors involved in the treatment decision include baseline clinical stage, location of the primary, and histology. Our previous data indicated that age, sex, and curative treatment were significant predictors of survival in patients with esophageal cancers lacking cancer stage and histology information13. Esophageal cancer exists as two distinct histological types: squamous cell carcinoma (SCC) and adenocarcinoma. There are marked differences between these carcinomas in terms of incidence, natural history and treatment outcomes14,15,16. Adenocarcinoma now is the leading cause of esophageal cancer in the United States, representing 80% of cases17. The question whether operable SCC of the esophageal cancer should be treated by radiotherapy or resection has been posed already three decades ago. Greater than 90% patients with esophageal cancer in our hospital have SCC. Therefore, we focus the role of surgery in the treatment of esophageal SCC compared with CCRT in the present study. It includes whether operable esophageal SCC should be treated by radiotherapy, resection or combined treatment, and if surgery provide a survival benefit in multidisciplinary treatment compared with definite CCRT for locally advanced esophageal SCC.

Results

Overall survival of patients with esophageal SCC

From 2007 to 2014, there were 1309 new cases diagnosed with esophageal cancer and with clinical stage T2-T4 and in our hospital. Among these patients, more than 90% was diagnosed with histologically confirmed SCC of esophagus. For clinical stage T2-T4 esophageal cancer, the median survival times were 1.06 year (95% CI 0.99-1.1 yrs) for patients with SCC, and 1.58 year (95% CI 0.85-3.21 yrs) for adenocarcinoma. To focus the role of surgery in the treatment of esophageal SCC, we conducted all further analysis on the basis of 1230 patients with T2-T4 esophageal SCC. The clinical characteristics are listed in Table 1. In our hospital, approximately 15 times as many males as females (1152 males and 78 females) had esophageal SCC diagnosed, and 30% patients received surgery as the major treatment modality for esophageal SCC. By survival analysis for patients with T2-T4 esophageal SCC (Fig. 1a), increasing age was associated with lower survival rates. In addition, as shown in Fig. 1b–c, clinical T stage and clinical lymph node (LN) involvement were significant predictor for prognosis. The 3-year survival rate was 45.9%; 22.9% and 13.7% for clinical T2, T3 and T4, respectively. The median survival time was 1.8 years (95% CI 1.45-2.96 yrs) in patients with clinical N0 and 1 year (95% CI 0.93-1.07 yrs) in those with clinical LN involvement.

Table 1

Characteristics of patients with T2-T4 esophageal SCC.

Figure 1

Overall survival in patients with T2-T4 esophageal SCC Kaplan-Meier survival curves of the total 1230 patients with clinical stage T2-T4 and histology confirmed with SCC; and the survival differences according to age (a), clinical T stage (b), and clinical...

Survival Rate of T2-T4 esophageal SCC by Treatment Modality

We further analyzed survival rate by treatment modality for patients with T2-T4 esophageal SCC. The overall 1- and 3-year survival rates after diagnosis were 52, and 22%, respectively. As shown in Fig. 1d, patients received surgery with or without (neo-) adjuvant treatment had significantly longer survival than patients treated with definite radiotherapy and chemotherapy. The median survival time was 2.46 years (95% CI 1.98-2.96 yrs) in patients treated with surgery, 0.85 years (95% CI 0.82-0.95 yrs) in those with definite CCRT, and 0.61 years (95% CI 0.54-0.76 yrs) in those with supportive or palliative treatment. Further multivariable Cox regression analysis of based on different co-variables showed that surgery with or without (neo-) adjuvant treatment could reduce more than 50% risk of death in T2-T4 stage, compared to those treated with definite CCRT (P < 0.001) (Fig. 2a). Figure 2b demonstrated that definite CCRT significantly improved survival compared to those only received palliative treatment. In addition, the details of treatment modality and treatment-related modality for each stage were shown in Fig. 2c. The data revealed that the treatment-related mortality (death occurred during or within 30 days after the completion treatment) rates in patients treated with curative intent surgery or CCRT. By the data, we found that surgery with or without (neo-)adjuvant treatment had no significant impact on treatment-mortality rate compared with that in CCRT group.

Figure 2

Treatment modality associated with prognosis of patients in multivariate model for patients with T2-T4 esophageal SCC Multivariable Cox regression analysis of based on different co-variables in patients with T2-T4 (a) Surgery+/−Neo/adjuvant Tx...

Treatment outcome of esophageal SCC by clinical stage

For patients with clinical stage T2-T3 esophageal SCC, as shown in Table 2, clinical T3 stage, clinical LN involvement, older ages, and no surgical resection were significantly associated with shorter survival time in univariate survival analysis. Further multivariable Cox regression analysis of based on different co-variables showed that surgery with or without (neo-) adjuvant treatment could reduce more than 50% risk of death in T2-T3 stage, compared to those treated with definite CCRT (Fig. 2a and Table 3). Furthermore, for the subgroup of patients with T3N(+) and T4, surgery combined with (neo-)adjuvant treatment obviously prolonged the survival rate compared to surgery alone or definite CCRT (Fig. 3a) (surgery alone versus definite CCRT, p = 0.179; surgery+ (neo-)adjuvant treatment versus definite CCRT, p < 0.001). For stage T4 esophageal SCC, there were only 90 patents (18%) received curative intent surgery. As shown in Fig. 3b, surgery combined with (neo-) adjuvant treatment provided the better overall survival rate than definite CCRT, with the median survival was 2.05 years (95% CI 1.57-2.90 yrs) and 0.78 years (95% CI 0.68-0.84 yrs), respectively. As shown in Fig. 2a and Table 4, multivariable survival analysis, surgery combined with (neo-)adjuvant treatment decreased 58% death risk compared to those treated with definite CCRT. In surgery group of patient with stage T2-T4, as shown in Fig. 3c, achieving pathologic complete response (pCR) after neoadjuvant treatment is a significant predictor for longer survival. For stage T2-T3, the 3-yr survival rate was 63.6% for patients with pCR, and 41.6% for patients without pCR (p = 0.013), respectively. For T4 esophageal SCC, the median survival is 4.41 years in patients received surgery with pathologic complete response, and 1.58 years in patients without pCR after neoadjuvant treatment. In addition, patients who treated with definite CCRT had significantly improved survival compared to those only received palliative treatment. In the group of definite CCRT, the radiation dose is the significant predictors for better overall survival (Fig. 3d).

Table 2

Adjusted hazard ratio of determine factors associated with prognosis of patients in univariate model for patients with T2-T3 esophageal SCC.

Table 3

Adjusted hazard ratio of determine factors associated with prognosis of patients in multivariate model for patients with T2-T3 esophageal cancer.

Table 4

Adjusted hazard ratio of determine factors associated with prognosis of patients in multivariate model for patients with T4 esophageal cancer.

Figure 3

Overall survivals in patients with esophageal SCC in subgroups of clinical stage and treatmentThe survival differences according to curative treatment modality in patients with T3N(+) and T4 (Surgery alone versus Surgery+Neo/adjuvant Tx versus definite...

Discussion

This was a retrospective study of the factors influencing the survival of patients with esophageal cancer, using the data of cancer registry and death registration in our hospital from 2007 to 2014. We previously showed that the survival of esophageal cancer patients who underwent surgery improved significantly compared with definite radiotherapy13. However, the limitations were the absence of the data about tumor stages, histologic tumor type and the details of treatment modalities. Therefore, an advantage of our analysis in the present study is that the results are based on a relative large population of esophageal cancer patients with information regarding tumor histology, staging and primary treatment detail.

In the western world, esophageal cancer has been considered a disease of the older population with a peak incidence between the sixth and seventh decades of life, and adenocarcinoma predominates17,18,19. According to the data of our hospital, the age of peak incidence of esophageal cancer was 50-64 years. Unsurprisingly, increasing age (>65 y/o) was associated with a marked decrease in overall survival rates similar to other studies20,21. The prevalence of esophageal cancer exhibited a marked sex difference, and it was a significant predictor for prognosis for T2-T3but not for T4 esophageal SCC.

For esophageal cancer, there are marked differences between adenocarcinoma and SCC in terms of natural history and treatment outcomes14,15,16. Although surgery is a major locoregional treatment5,22,23, the curative potential of CCRT reported in several studies have challenged the role of surgery in esophageal cancer11,12. The most appropriate treatment modality for esophageal SCC is still controversial. Greater than 90% patients with esophageal cancer in our hospital have SCC. Therefore, we focus on if surgery provides a survival benefit in esophageal SCC in the present study. Multivariate analysis of based on different co-variables showed that surgery with or without (neo-) adjuvant treatment could reduce more than 50% risk of death in T2-T4 stage, compared to those treated with definite CCRT. Furthermore, compared to patients without curative treatment, definite CCRT significantly increased the overall survival rate. The appropriate radiation dose for definite CCRT is controversial. Although 50.4 Gy remains the Radiation therapy Oncology Group (RTOG) standard dose for radiation with delivered concurrently with chemotherapy24,25, RT dose up to at least 60 Gy was used in randomized trials comparing definitive CCRT vs surgery11,12,26. Our survival analysis revealed that definite CCRT had lower survival rate than that underwent surgical resection, but the higher doses of radiation (>=60Gy) is significant benefit to survival. Therefore, by our database, surgery provided a survival benefit compared to definite CCRT, and radiotherapy dose should be higher than 60Gy for patients treated with definite CCRT.

It has been reported that the 5-year survival rate post-esophagectomy was 52% for patients with no residual tumor, but decreased to only 14% if residual tumors were present27. To increase the possibility of complete resection, more than 85% of patients with T2-3N (+) and T4 who underwent surgical resection received (neo-) adjuvant treatment in our hospital. For esophageal adenocarcinoma, it has been reported that (neo-) adjuvant radiotherapy are of significant survival benefit to T3N0M0 stage, but not significantly good to T2N0M028. By the database in our hospital, (neo-) adjuvant treatment had significant survival benefit to stage T3N(+) and T4, but not to stage T2N(+). Furthermore, in surgery group of stage T2-T4, univariate survival analyses showed that survival time was associated with clinical T stage, LN involvement and pathologic complete response. The presence of pathologic complete response (pCR) has been shown to be a significant prognostic factor for local and distant recurrence in esophageal cancer patients receiving trimodality therapy29,30,31. The pCR rate of 18% in our study was low relative to that reported in other studies ranged from 20% to 40%32,33,34. The potential reasons included the difference in chemotherapy agents, radiotherapy doses received, as well as the quality and expertise of the pathologists who analyzed the surgical specimen. Treatment-related mortality is an important issue to guide if multidisciplinary therapy is benefit for survival35. In patients with stage T2-4, (neo-)adjuvant treatment didn’t increase the treatment-related mortality in surgery group of our hospital. Therefore, improvement in surgical techniques and perioperative risk evaluation might explain why surgery significantly increased overall survival rate of esophageal cancer patients demonstrated by multivariable analysis, at least in part.

The reported incidence of stage T4 is 12–34% among thoracic esophageal cancer36,37 with a false positive rate of approximately 40%38,39. For T4 esophageal SCC, it is still unclear if the addition of surgery provided survival benefit in patients with compared with definite CCRT. Previous studies reported the effectiveness of definite CCRT in advanced esophageal cancer including T4 tumors40,41. Although only 18% of T4 patients in our hospital received surgical resection, survival analysis showed that surgery with (neo-) adjuvant treatment offers a favorable overall survival compared with definite CCRT by uni- and multivariable analysis. With respect to superior local control and higher false positive rate of clinical T4, it is an important issue about what population of patients with T4 tumors would achieve survival benefit by undergoing resection after neoadjuvant CCRT40. Randomized controlled trials involving large population samples are needed to define the standard treatment for T4 esophageal cancer.

The limitations to our study are related to the inherent nature of investigating a hospital-based registry. We are unable to ascertain the reason for the delay in initiation of curative treatment or the choice of palliative treatment. Furthermore, we could not account for potential unmeasured selection biases regarding performance status, comorbidity, access to health care, or other patient-related factors.

Conclusions

Esophageal cancer is a particularly devastating form of cancer with a relatively low survival rate. By outcome analysis, we demonstrated that treatment with surgery is significantly linked with better survival rate in patients with esophageal SCC. Therefore, curative resection should be considered for esophageal cancer patients who are medically fit for surgery.

Materials and Methods

Data source

The data source comes from our hospital Cancer Registry and death registration (CGRD) in this study. CGRD is a high quality cancer registry and provides sufficient information regarding individual demographics, stage of disease, tumor histology, and primary treatment details.

Study population and study design

This study adhered to strict confidentiality guidelines, in accordance with regulations regarding personal electronic data protection, and was approved by the Institutional Review Board of Chang Gung Memorial hospital. From the database, we included all subjects who were newly diagnosed with esophageal cancer between January 1, 2007 and December 31, 2014, and all medical records of the esophageal cancer cohort were extracted and analyzed. The patients with other cancers diagnosis before the first day of esophageal cancer diagnosis in the records of CGRD was excluded from this study. All enrolled study subjects were followed-up until death or the end of 2015. Our study flow chart was depicted in Fig. 4. From 2007 to 2014, CGRD database provided a total 2489 cases in whom esophageal cancer was diagnosed as the first malignancy, and complete data were available for analysis. We further excluded 1018 patients with stage M1 and 162 patients with clinical stage Tis-T1 at diagnosis from this study. To focus the prognosis of esophageal SCC, a total of 1230 patients had a diagnosis of histologically confirmed SCC of esophagus with clinical stage T2-T4 enrolled into our study. The curative treatment for T2-T4 esophageal cancer was according to the guidelines proposed by oncology team at our hospital. Surgery is considered for all physiologically fit patients with localized, resectable, esophageal cancer. If surgery was contraindicated or the patients refused it, they received definite CCRT with radiotherapy dose for 40–66Gy. In this study, we included patient demographic (age, gender), disease characteristics (tumor location, clinical T-stage and N-stage), and treatment characteristics.

Figure 4

Study flow chart We enrolled the patients with clinical stage T2-T4N0-N(+) esophageal SCC into our present study.

Statistical analysis

We used the Kaplan-Meier method to calculate survival curves and the log-rank test to compare the two groups for difference in survival curves. Finally, Cox proportional hazards models were used to compute the hazard ratios (HRs) accompanying 95% confidence intervals (CIs) after adjustment for esophageal cancer treatment and clinical characteristics. All of these analyses were conducted using SAS statistical software (version 9.2; SAS Institute, Cary, NC, USA).

Additional Information

How to cite this article: Chen, M.-F. et al. Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci. Rep.7, 46139; doi: 10.1038/srep46139 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgments

This work was supported by research grants from Chang Gung Memorial Hospital (CORPG6D0162).

Footnotes

The authors declare no competing financial interests.

Author Contributions M.F.C. participated in its design and statistical analysis, performed the study, and drafted the manuscript. P.T.C. and M.S.L. conceived of the study and participated in its design and coordination. C.P.L. participated in statistical analysis. W.C.C. participated in its design and statistical analysis, and coordination and assisted in editing of manuscript.

References

  • Parkin D. M., Bray F., Ferlay J. & Pisani P. Global cancer statistics, 2002. CA Cancer J Clin55, 74–108 (2005). [PubMed]
  • Kelsen D. P. et al. . Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol25, 3719–3725, doi: 10.1200/JCO.2006.10.4760 (2007). [PubMed][Cross Ref]
  • Allum W. H., Stenning S. P., Bancewicz J., Clark P. I. & Langley R. E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol27, 5062–5067, doi: 10.1200/JCO.2009.22.2083 (2009). [PubMed][Cross Ref]
  • Napier K. J., Scheerer M. & Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol6, 112–120, doi: 10.4251/wjgo.v6.i5.112 (2014). [PMC free article][PubMed][Cross Ref]
  • Amenabar A., Hoppo T. & Jobe B. A. Surgical management of gastroesophageal junction tumors. Semin Radiat Oncol23, 16–23, doi: 10.1016/j.semradonc.2012.09.002 (2013). [PubMed][Cross Ref]
  • Stahl M. Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?Ann Oncol21 Suppl 7, vii283–285, doi: 10.1093/annonc/mdq294 (2010). [PubMed][Cross Ref]
  • Steyerberg E. W. et al. . Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol24, 4277–4284, doi: 10.1200/JCO.2005.05.0658 (2006). [PubMed][Cross Ref]
  • Baba Y., Watanabe M., Yoshida N. & Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol6, 121–128, doi: 10.4251/wjgo.v6.i5.121 (2014). [PMC free article][PubMed][Cross Ref]
  • Jang R., Darling G. & Wong R. K. Multimodality approaches for the curative treatment of esophageal cancer. J Natl Compr Canc Netw13, 229–238 (2015). [PubMed]
  • Fokas E., Weiss C. & Rodel C. The role of radiotherapy in the multimodal management of esophageal cancer. Dig Dis31, 30–37, doi: 10.1159/000347170 (2013). [PubMed][Cross Ref]
  • Stahl M. et al. . Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol23, 2310–2317, doi: 10.1200/JCO.2005.00.034 (2005). [PubMed][Cross Ref]
  • Bedenne L. et al. . Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol25, 1160–1168, doi: 10.1200/JCO.2005.04.7118 (2007). [PubMed][Cross Ref]
  • Chen M. F., Yang Y. H., Lai C. H., Chen P. C. & Chen W. C. Outcome of patients with esophageal cancer: a nationwide analysis. Ann Surg Oncol. 20, 3023–30. doi: 10.1245/s10434-013-2935-4 (2013). [PubMed][Cross Ref]
  • Siewert J. R. et al. . Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg234, 360–367, discussion 368-369 (2001). [PMC free article][PubMed]
  • Mariette C., Finzi L., Piessen G., Van Seuningen I. & Triboulet J. P. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg29, 39–45, doi: 10.1007/s00268-004-7542-x (2005). [PubMed][Cross Ref]
  • Rohatgi P. R. et al. . Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer106, 552–558, doi: 10.1002/cncr.21601 (2006). [PubMed][Cross Ref]
  • Brown L. M., Devesa S. S. & Chow W. H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst100, 1184–1187, doi: 10.1093/jnci/djn211 (2008). [PMC free article][PubMed][Cross Ref]
  • van Blankenstein M., Looman C. W., Siersema P. D., Kuipers E. J. & Coebergh J. W. Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br J Cancer96, 1767–1771, doi: 10.1038/sj.bjc.6603798 (2007). [PMC free article][PubMed][Cross Ref]
  • Guardino J. M. et al. . Barrett’s esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol101, 2187–2193, doi: 10.1111/j.1572-0241.2006.00736.x (2006). [PubMed][Cross Ref]
  • Gavin A. T. et al. . Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol36, 505–512, doi: 10.1016/j.canep.2012.07.009 (2012). [PubMed][Cross Ref]
  • Wo J. Y., Hong T. S. & Kachnic L. A. Impact of age and comorbidities on the treatment of gastrointestinal malignancies. Semin Radiat Oncol22, 311–320, doi: 10.1016/j.semradonc.2012.05.008 (2012). [PubMed][Cross Ref]
  • Fuchs H. F. & Holscher A. H. [Therapeutic decisions in patients with operable, non-metastatic oesophageal cancer]. Zentralbl Chir139, 32–36, doi: 10.1055/s-0033-1360295 (2014). [PubMed][Cross Ref]
  • Pennathur A., Gibson M. K., Jobe B. A. & Luketich J. D. Oesophageal carcinoma. Lancet381, 400–412, doi: 10.1016/S0140-6736(12)60643-6 (2013). [PubMed][Cross Ref]
  • Minsky B. D. et al. . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol20, 1167–1174 (2002). [PubMed]
  • Yamoah K., Showalter T. N. & Ohri N. Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials. Int J Radiat Oncol Biol Phys93, 737–745, doi: 10.1016/j.ijrobp.2015.07.2284 (2015). [PMC free article][PubMed][Cross Ref]
  • Chiu P. W. et al. . Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg9, 794–802 (2005). [PubMed]
  • Tachimori Y. et al. . Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus13, 110–137, doi: 10.1007/s10388-016-0531-y (2016). [PMC free article][PubMed][Cross Ref]
  • Song Y. et al. . Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma. Oncotarget7, 21347–21352, doi: 10.18632/oncotarget.7256 (2016). [PMC free article][PubMed][Cross Ref]
  • Chirieac L. R. et al. . Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer103, 1347–1355, doi: 10.1002/cncr.20916 (2005). [PubMed][Cross Ref]
  • Berger A. C. et al. . Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol23, 4330–4337, doi: 10.1200/JCO.2005.05.017 (2005). [PubMed][Cross Ref]
  • Stahl M. et al. . Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol27, 851–856, doi: 10.1200/JCO.2008.17.0506 (2009). [PubMed][Cross Ref]
  • Tepper J. et al. . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol26, 1086–1092, doi: 10.1200/JCO.2007.12.9593 (2008). [PMC free article][PubMed][Cross Ref]
  • van Hagen P. et al. . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med366, 2074–2084, doi: 10.1056/NEJMoa1112088 (2012). [PubMed][Cross Ref]
  • Tessier W. et al. . Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer?Ann Thorac Surg97, 1181–1189, doi: 10.1016/j.athoracsur.2013.12.026 (2014). [PubMed][Cross Ref]
  • Smithers B. M. & Thomson I. Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer. Thorac Surg Clin23, 509–523, doi: 10.1016/j.thorsurg.2013.07.005 (2013). [PubMed][Cross Ref]
  • Lerut T. E. et al. . Advanced esophageal carcinoma. World J Surg18, 379–387 (1994). [PubMed]
  • Holscher A. H. et al. . Prognostic factors of resected adenocarcinoma of the esophagus. Surgery118, 845–855 (1995). [PubMed]
  • de Manzoni G. et al. . Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol95, 261–266, doi: 10.1002/jso.20640 (2007). [PubMed][Cross Ref]
  • Matsubara T. et al. . Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg25, 279–284, doi: 10.1007/s002680020060 (2001). [PubMed][Cross Ref]
  • Tsujinaka T. et al. . Role of preoperative chemoradiation in the management of upper third thoracic esophageal squamous cell carcinoma. Am J Surg177, 503–506; discussion 507 (1999). [PubMed]
  • Makino T. & Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg17, 221–228 (2011). [PubMed]

1. Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher A, Müller RP. Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlenther Onkol. 2012;188:226–232.[PubMed]

2. Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38:599–604.[PubMed]

3. Zhang JQ, Hooker CM, Brock MV, Shin J, Lee S, How R, Franco N, Prevas H, Hulbert A, Yang SC. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg. 2012;93:429–435; discussion 436-437.[PMC free article][PubMed]

4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trfotti A. Cancer staging handbook. 7th ed. Springer Science Business Media: 2009. pp. 138–142.

5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.[PubMed]

6. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14:2687–2690.[PubMed]

7. United States National Institutes of Health. Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma (TOPGEAR) 2013. Available from: http: //www.clinicaltrials.gov/ct2/show/NCT01924819?term=TROG 08.08&rank=1.

8. Andreollo NA, Tercioti Jr V, Lopes LR, de Souza Coelho-Neto J. Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus. Arq Gastroenterol. 2013;50:101–106.[PubMed]

9. Cao XF, He XT, Ji L, Xiao J, Lv J. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:477–481.[PubMed]

10. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mäntyla M, Modig H, Munck-Wikland E, Rosengren B. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16:1104–1109; discussion 1110.[PubMed]

11. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467.[PubMed]

12. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161–167.[PubMed]

13. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–313.[PubMed]

14. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659–668.[PubMed]

15. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–1092.[PMC free article][PubMed]

16. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.[PubMed]

17. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, et al. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012;83:300–304.[PMC free article][PubMed]

18. Kranzfelder M, Schuster T, Geinitz H, Friess H, Büchler P. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 2011;98:768–783.[PubMed]

19. Yamamoto M, Yamashita T, Matsubara T, Kitahara T, Sekiguchi K, Furukawa M, Uki A, Kobayashi M, Tanaka E, Ueda M, et al. Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1997;37:75–78.[PubMed]

20. Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, Gu XZ, Zhang DC, Zhang RG, Wang LJ. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003;75:331–336.[PubMed]

21. Zieren HU, Müller JM, Jacobi CA, Pichlmaier H, Müller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995;19:444–449.[PubMed]

22. Ténière P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet. 1991;173:123–130.[PubMed]

23. Kunath U, Fischer P. [Radical nature and life expectancy in the surgical treatment of esophageal and cardial carcinoma] Dtsch Med Wochenschr. 1984;109:450–453.[PubMed]

24. Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery. 1993;113:138–147.[PubMed]

25. Schreiber D, Rineer J, Vongtama D, Wortham A, Han P, Schwartz D, Choi K, Rotman M. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244–250.[PubMed]

26. Bédard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer. 2001;91:2423–2430.[PubMed]

27. Xu Y, Liu J, Du X, Sun X, Zheng Y, Chen J, Li B, Liu W, Jiang H, Mao W. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol. 2013;8:116.[PMC free article][PubMed]

28. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–730.[PubMed]

29. Jabbour SK, Thomas CR. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol. 2010;1:102–111.[PMC free article][PubMed]

30. United States National Institutes of Health. Neoadjuvant vs adjuvant therapy in treating resectable thoracic esophageal cancer. 2011. Available from: http:// www.clinicaltrials.gov.

31. Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol. 2012;10:173.[PMC free article][PubMed]

32. United States National Institutes of Health. Quality of life in neoadjuvant vs adjuvant therapy of esophageal cancer treatment trial. Available from: http:// www.clinicaltrials.gov.

33. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–2317.[PubMed]

34. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–1168.[PubMed]

35. Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012;82:1967–1972.[PMC free article][PubMed]

36. Makino T, Doki Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17:221–228.[PubMed]

37. Rosenblatt E, Jones G, Sur RK, Donde B, Salvajoli JV, Ghosh-Laskar S, Frobe A, Suleiman A, Xiao Z, Nag S. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother Oncol. 2010;97:488–494.[PubMed]

38. Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000;88:988–995.[PubMed]

39. Vuong T, Szego P, David M, Evans M, Parent J, Mayrand S, Corns R, Burtin P, Faria S, Devic S. The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. Int J Radiat Oncol Biol Phys. 2005;63:758–764.[PubMed]

40. Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, Li GZ. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247:574–581.[PubMed]

41. Tai P, Van Dyk J, Yu E, Battista J, Stitt L, Coad T. Variability of target volume delineation in cervical esophageal cancer. Int J Radiat Oncol Biol Phys. 1998;42:277–288.[PubMed]

42. Miller C. Carcinoma of thoracic oesophagus and cardia. A review of 405 cases. Br J Surg. 1962;49:507–522.[PubMed]

43. Breunig J, Hernandez S, Lin J, Alsager S, Dumstorf C, Price J, Steber J, Garza R, Nagda S, Melian E, et al. A system for continual quality improvement of normal tissue delineation for radiation therapy treatment planning. Int J Radiat Oncol Biol Phys. 2012;83:e703–e708.[PubMed]

44. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–1174.[PubMed]

45. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, Cox JD, Starkschall G. Quantifying the interfractional displacement of the gastroesophageal junction during radiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83:e273–e280.[PMC free article][PubMed]

46. Yu E, Dar R, Rodrigues GB, Stitt L, Videtic GM, Truong P, Tomiak A, Ash R, Brecevic E, Inculet R, et al. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients? Radiother Oncol. 2004;73:141–148.[PubMed]

47. Yu E, Tai P, Younus J, Malthaner R, Truong P, Stitt L, Rodrigues G, Ash R, Dar R, Yaremko B, et al. Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience. Curr Oncol. 2009;16:48–54.[PMC free article][PubMed]

48. Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D’Souza WD, Suntharalingam M, Lu W. Spatial-temporal [18F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85:1375–1382.[PMC free article][PubMed]

49. Benefit of PET or PET/CT in oesophageal cancer is not proven. 2013. Available from: https: //www.iqwig.de/en/press/press_releases/press_releases/benefit_of_pet_or_pet/ct_in_oesophageal_cancer_is_not_proven.3698.html.

50. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598.[PubMed]

51. Blackstock AW, Russo S. Cancer of the esophagus. In: Gunderson LL, Tepper JE, editors. Clinical RT oncology. 3rd ed. Elsevier Saunders: Philadelphia; 2012. p. 855.

52.

0 Replies to “Case Study 32 Esophageal Cancer Treated With Surgery And Radiation”

Lascia un Commento

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *